Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if sorafenib improves the effectiveness of
a procedure called radiofrequency ablation (RFA) for the treatment of hepatocellular cancer
(HCC). Radiofrequency ablation has been used to treat many types of tumors, including
hepatocellular cancers. During RFA a needle is inserted into the tumor tissue and heat is
used to kill the tumor cells. Sorafenib has been approved by the FDA for the treatment of
hepatocellular cancer that cannot be treated with surgery. Pre-clinical data suggests that
sorafenib may improve the efficacy of RFA.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute
Collaborators:
Bayer Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute National Cancer Institute (NCI) Onyx Therapeutics, Inc.